In this article, we will discuss Olaparib (Patient Selection-2). So, let’s get started.
- Patient Selection for gBRCAm HER2-negative Metastatic Breast Cancer
- Select patients for the treatment of HER2-negative metastatic breast cancer with Lynparza based on the presence of deleterious or suspected deleterious gBRCA-mutation.